[January 24-28, 2016]
The conference showcased cutting-edge anti-parasitic drug discovery programs that illustrate the path from parasite biology to lead identification and from optimization to candidate selection.
Stéphanie Braillard, Béatrice Bonnet, Eric Chatelain, Charles Mowbray, and Ivan Scandale participated in this conference on drug discovery for parasitic diseases.
|The NTD Drug Discovery Booster: a novel approach for hit to lead chemistry.
Charles Mowbray, Head of Drug Discovery, DNDi
Poster Teaser Talk
|DNDI-0690: A new promising drug candidate for the treatment of visceral leishmaniasis.
Stéphanie Braillard*, Beatrice Bonnet, Eric Chatelain
|Tailored hit-discovery cascades for Leishmania donovani and Trypanosoma cruzi that combine high-throughput screening with multiple secondary assays to build confidence in hits
De Rycker M*, Brand S, Comer E, Cotillo-Torrejon I, Fairlamb A, Ferguson M, Fiandor JM, Gilbert I, Gray D, Jean-Robert Ioset, Ko EJ, MacLean L, Manthri S, Marco-Martin M, Martin-Plaza JJ, Miles T, Nühs A, Osuna-Cabello M, Pena-Urquiza I, Read K, Riley J, Robinson D, Scherer C, Sandberg L, Schreiber S, Simeons F, Stojanovski L, Thomas J, Thomas M, Thompson S, Torrie L, Wyatt P.
|Development of new drugs for Visceral Leishmaniasis and Chagas disease: Translational challenges and what we can learn from in vitro and in vivo profiling of reference drugs and new chemical series.
Eric Chatelain, Stéphanie Braillard
|Discovery program for identification macrofilaricide agents for treatment of Onchocerciasis
Hawryluk, N. Canan, S, Chojnowski A, Kreiss T, Prorok M, Siekierka J, Khetani V, Zeldis J, Ivan Scandale, Townson S, Gokool S, Hubner M, Hoerauf A, Martin C.
* Presenting author
More information: Keystone Symposia Conference website